Caribou Biosciences’ restructuring narrows the biotech’s focus to two off-the-shelf cell therapies for blood cancers, whose key data readouts have been pushed out to the second half of 2025. It’s the CRISPR-editing company’s second cash-saving restructuring in the past year.
The post CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies appeared first on MedCity News.
